These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11389071)

  • 21. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
    Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
    Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.
    Pollack IF; Bredel M; Erff M; Hamilton AD; Sebti SM
    Neurosurgery; 1999 Nov; 45(5):1208-14; discussion 1214-5. PubMed ID: 10549939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
    Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
    Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
    Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
    Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
    Cohen-Jonathan E; Evans SM; Koch CJ; Muschel RJ; McKenna WG; Wu J; Bernhard EJ
    Cancer Res; 2001 Mar; 61(5):2289-93. PubMed ID: 11280800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
    Ren H; Tai SK; Khuri F; Chu Z; Mao L
    Cancer Res; 2005 Jul; 65(13):5841-7. PubMed ID: 15994961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of potential markers of farnesyltransferase inhibition.
    Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
    Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
    Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
    Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
    Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.